TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05737901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Booklet
Description: Training titles and contents were created by listing the most common complications and needs of patients after CABG surgery. In the General Information section of the booklet, the definition of CAD, how CABG surgery is performed, the length of hospital stay, and what can be experienced in the hospital after surgery and in the home environment after discharge were discussed. In the Postoperative Self-Care Practices section, information about the healing process of the breastbone, pain management, medication, respiratory exercises, early nutrition, personal hygiene, protection from coronavirus-19, pulse control, postoperative heart attack, conditions to be reported, compression stockings use for varicose veins, physical activity, travel, sleep and rest, sexual life, and coping with stress and depression was presented. In the Postoperative Life section, training topics on exercise, nutrition, smoking, and alcohol use were included.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: The logo and content of the Bypass e-Discharge application was visually designed, and the software was developed. In-app transactions were secured with end-to-end encryption by entering the username and password, and internet access was not required to use the application. The application was presented for expert opinion (3 patients, 1 academician, 2 nurses, 2 physicians) in order to investigate the user experience, and edits were made on its interface (such as adding the acceleration feature in videos, an additional button for stopping and starting videos, displaying video total time on the screen, and magnification of all buttons).
Study: NCT01218815

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IRA stenting in culprit lesion only
Description: stenting

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IRA stenting
Description: Complete IRA revascularization
Study: NCT04458857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Dose A or Dose B subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT02553824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine/Topiramate-First
Description: Patients randomly assigned to this Arm will have a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning. For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated). Then will have a 2 week washout followed by a crossover to 12 weeks of control medication/ placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phentermine/Topiramate-First
Description: Patients randomly assigned to this Arm will have a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning. For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated). Then will have a 2 week washout followed by a crossover to 12 weeks of control medication/ placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients randomly assigned to this Arm will have begin with 12 weeks of placebo followed by a 2 week washout. They will then crossover to Qsymia and receive a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning. For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomly assigned to this Arm will have begin with 12 weeks of placebo followed by a 2 week washout. They will then crossover to Qsymia and receive a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning. For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated).
Study: NCT02666989

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: 2 placebo pills twice a day
Study: NCT04567004

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Participants will be shown images of juice, bread, yogurt, cookies, and cereal without any added front-of-package labels.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutriscore Label
Description: A front-of-package Nutriscore label will be applied to images of juice, bread, yogurt, cookies, and cereal. This label applies a score of A, B, C, D, or E based on the product's nutrition profile.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted Peruvian Nutrient Label
Description: A front-of-package octagonal nutrient label will be applied to images of juice, bread, yogurt, cookies, and cereal. The label text informs consumers if a product is high in sugar, saturated fat, or salt/sodium. These labels were developed by the Peruvian government and adapted by investigators.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guideline Daily Amount Label
Description: A front-of-package Guideline Daily Amount label will be applied to images of juice, bread, yogurt, cookies, and cereal. The label shows the amount and percent of daily value of calories, total fat, saturated fat, sugar, and sodium in one serving of a product.
Study: NCT02641275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured self-management-training
Description: Structured self-management-training (incl. systemic analysis, coaching, teaching) in 4 sessions
Study: NCT01951599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: Volunteers will receive a single 20-mg dose of AZD9291 as a capsule on day 1, in Part A, Period 1, in the fasted state. (Treatment A).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: Volunteers will receive a single 20-mg dose of AZD9291 as a solution on day 1, in Part A, Period 2, in the fasted state. (Treatment B).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: Volunteers will receive a single 20-mg dose of AZD9291 as a tablet on day 1, in Part A, Period 3, in the fasted state. (Treatment C).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: Volunteers will receive a single 20-mg dose of AZD9291 as a capsule or tablet on day 1, in Part B, Period 1, in the fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: Volunteers will receive a single 20-mg dose of AZD9291 as a capsule or tablet on day 1, in Part B, Period 2, in the fed state.
Study: NCT02299388

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide or Placebo
Description: All subjects will be advised a low sodium diet. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide or Placebo
Description: All subjects will be advised a low sodium diet. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval.
Study: NCT03826537

Intervention type: OTHER
Group type: OTHER
Intervention: Honey substance
Description: Honey substance containing 5.1 mg/kg tutin and 23 mg/kg hyenanchin
Study: NCT03893760

Intervention type: DIAGNOSTIC_TEST
Intervention: Ventriculo-arterial coupling assessment (R-V/A)
Description: R-V/A was achieved by computing the R-Elv/P-Ea ratio (Right ventricular elastance/Pulmonary arterial elastance). R-Elv was computed as PAPm / end-systolic area (ESA) of the right ventricle. P-Ea was obtained as (PAPm-PCWP)/ right ventricle stroke volume (R-SV).

Intervention type: DIAGNOSTIC_TEST
Intervention: Ventriculo-arterial coupling assessment (R-V/A)
Description: R-V/A was achieved by computing the R-Elv/P-Ea ratio (Right ventricular elastance/Pulmonary arterial elastance). R-Elv was computed as PAPm / end-systolic area (ESA) of the right ventricle. P-Ea was obtained as (PAPm-PCWP)/ right ventricle stroke volume (R-SV).

Intervention type: DIAGNOSTIC_TEST
Intervention: Ventriculo-arterial coupling assessment (R-V/A)
Description: R-V/A was achieved by computing the R-Elv/P-Ea ratio (Right ventricular elastance/Pulmonary arterial elastance). R-Elv was computed as PAPm / end-systolic area (ESA) of the right ventricle. P-Ea was obtained as (PAPm-PCWP)/ right ventricle stroke volume (R-SV).
Study: NCT02403804

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Phosphatidylcholine
Description: Phosphatidylcholine 3600 mg qam and 2700 mg qpm

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Betaine (588 mg qam and 412 mg qpm)
Description: Betaine anhydrous 588 mg qam and 412 mg qpm

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Betaine (1000 mg BID)
Description: Betaine anhydrous 1000 mg BID
Study: NCT00701688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Dose level 1 40 mcg/kg/day intravenous Dose level 2 60 mcg/kg/day intravenous Dose level 3 90 mcg/kg/day intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Dose level 1 40 mcg/kg/day intravenous Dose level 2 60 mcg/kg/day intravenous Dose level 3 90 mcg/kg/day intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Dose level 1 40 mcg/kg/day intravenous Dose level 2 60 mcg/kg/day intravenous Dose level 3 90 mcg/kg/day intravenous
Study: NCT01560026

Intervention type: PROCEDURE
Intervention: surgery
Description: endometrial cancer with or without oophorectomy
Study: NCT02318888

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icodextrin
Study: NCT03280056

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NurOwn® (MSC-NTF cells)
Description: NurOwn® (MSC-NTF): One course of treatment that includes three separate intrathecal injections of 100-125 x 10\^6 cells every 8 weeks~NurOwn® (MSC-NTF): Autologous, bone marrow-derived, mesenchymal stem cells secreting neurotrophic factors

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One course of treatment that includes three separate intrathecal injections of Placebo every 8 weeks~Placebo: liquid solution in syringe for injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow aspiration
Description: Bone Marrow aspiration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bone Marrow aspiration
Description: Bone Marrow aspiration
Study: NCT03723863

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: Receive in-person occupational therapist-led work consultation
Study: NCT01588158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 325 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vicodin
Description: Vicodin 5/325 mg
Study: NCT04254081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.15 MG
Description: Buprenorphine 0.15mg solution will be added to a 20mL 1% buffered lidocaine solution (paracervical block) which will be administered in the paracervical space prior to osmotic dilator insertion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine 1% Injectable Solution
Description: 20mL of 1% buffered lidocaine solution (paracervical block) will be administered in the paracervical space prior to osmotic dilator insertion.
Study: NCT02966847

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CBCT acquisition
Description: Acquisitions are performed with the DynaCT function of a C-arm Artis Zeego System® device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anesthesia and surgery
Description: The anesthesia and surgery will take place according clinical routine practice
Study: NCT03285035

Intervention type: DEVICE
Intervention: Administration of questionaires to patients receiving an upper endoscopy with cryotherapy in addition to chemotherapy for esophageal cancer palliation.
Description: Upper endoscopy with cryotherapy using liquid nitrogen.
Study: NCT01252407

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical nerve stimulation
Description: Application of low frequency (10-Hz) and high frequency (100-Hz) TENS, in two different days
Study: NCT01966887

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: MYDICAR-single intracoronary infusion
Description: AAV1/Serca2a

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: Placebo; single intracoronary infusion
Description: single intracoronary infusion
Study: NCT02247882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: The educational program will comprise a multidisciplinary team: doctor, pharmacist, nurse, nutritionist, psychologist, physiotherapist and physical educator. Classes will be weekly in groups for eight weeks, with a duration of two hours.~The education program will include the following items: guidelines about the disease and its complications, strategies for pain management (pharmacological and cognitive), physical exercise, nutrition and weight control, medication (type, interactions, current trends, side effects ), balance, proprioception, fall prevention, coping with chronic pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aquatic Physical Therapy
Description: The exercise protocol will consist of: five minutes of heating with walking and patellar mobilization; ten minutes stretching the muscles of the lower limbs (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings); ten minutes isometric and dynamic exercises with elastic (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings); twenty minutes away from aerobic exercise (stationary running deep running water); ten minutes in functional training step and proprioceptive exercises; and five minutes of cooling with stretching of muscles of lower limbs (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings).
Study: NCT00816127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: intranasal desmopressin (300μg)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood transfusion
Description: fresh frozen plasma 10ml/kg and/or 1 unit of single donor platelets
Study: NCT03072290

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: ultrasound-guided injection using 1ml of 10 mg (10mg/ml) or 40 mg (40 mg/ml) triamcinolone acetonide (Shincort)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: ultrasound-guided injection using 1ml of 10 mg (10mg/ml) or 40 mg (40 mg/ml) triamcinolone acetonide (Shincort)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine hydrochloride
Description: ultrasound-guided injection using 1 ml of 2% lidocaine hydrochloride (Xylocaine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine hydrochloride
Description: ultrasound-guided injection using 1 ml of 2% lidocaine hydrochloride (Xylocaine)
Study: NCT02575196

Intervention type: DEVICE
Intervention: Non-invasive cerebral flow monitoring
Description: As soon as possible after ROSC, c-flow monitor will be connected to the patient, recording cerebral flow index for the first 72 hours following ROSC. All other relevant clinical data will be recorded.
Study: NCT03072095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-only
Description: Subjects will receive a text communication indicating they are overdue for colon cancer screening with the option to elect to receive a free, at-home FIT kit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text + Lottery
Description: Subjects will receive a text communication indicating they are overdue for colon cancer screening with the option to elect to receive a free, at-home FIT kit and a 1 in 5 chance to win a $100 gift card for completing the kit.
Study: NCT00816777

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemoembolization with irinotecan Bead
Description: Intra arterial chemoembolization using Irinotecan Bead 100mg irinotecan per procedure in combination with irinotecan monotherapy 250mg/m2 alternating on a 3 weekly schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan monotherapy: 250mg/m2 repeated every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan monotherapy: 250mg/m2 repeated every 3 weeks
Study: NCT02597738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh tissue biopsy
Description: Fresh tissue biopsy will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh tissue biopsy
Description: Fresh tissue biopsy will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood/Urine Sample Collection
Description: A one time blood sample will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood/Urine Sample Collection
Description: A one time blood sample will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood/Urine Sample Collection
Description: A one time blood sample will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood/Urine Sample Collection
Description: A one time blood sample will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood/Urine Sample Collection
Description: A one time blood sample will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood/Urine Sample Collection
Description: A one time blood sample will be collected.
Study: NCT03227731

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Truvada
Description: Truvada (Truvada (emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) is in a fixed-dose combination (FDC) tablet formulation and is proven safe for the prevention and treatment of HIV in non-pregnant and non-lactating women.
Study: NCT03383224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: genotype-guided therapy
Description: treatment based on patient's CHRNA5 rs16969968 genotype

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: genotype-guided therapy
Description: treatment based on patient's CHRNA5 rs16969968 genotype

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Study: NCT00945412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micropolysaccharide Hemospheres (Arista)
Description: MPH is applied as an aerosolized powder which is applied to the bleeding fossa, immediately after suctioning the freshly completed tonsillotomy site to expose the tonsil bed. A separate aerosolizer is used for each patient in order to maximize uniformity per standard dose applied. Each initial dose remains in situ for up to 60 seconds in an attempt to achieve complete hemostasis with a single dose. (Prior data from MPH use has shown that 30-60 seconds is the time typically required for hemostasis for diffuse, non-arterial bleeds.) If there is persistent bleeding after this timeframe, then the bed is irrigated and suctioned and a second equivalent dose is applied.~No pressure pack and no oxymetazoline or other topical vasoconstrictor is applied in either group during these initial hemostatic steps, since they are potential confounders of hemostatic effect.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocautery (Monopolar suction cautery)
Description: Monopolar suction electrocautery is used at 20 Watts. Cautery is applied with a light surface touch until bleeding has stopped. In addition, any prominent visible vessels are cauterized.
Study: NCT02004938

Intervention type: DEVICE
Intervention: Sonosite Titan Ultrasound Machine
Study: NCT02300623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy plus Interleukin-2
Description: Daily s.c. IL-2: 750,000 UI/m2/day for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiretroviral therapy alone
Description: Standard antiretroviral therapy
Study: NCT03501524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VATS evacuation
Description: the patient will be randomized to a Video-Assisted thoracoscopy for retained haemothorax

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VATS evacuation
Description: the patient will be randomized to a Video-Assisted thoracoscopy for retained haemothorax

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thoracostomy tube
Description: the patient is randomized to reinsertion of a Thoracostomy Tube for retained haemothorax

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thoracostomy tube
Description: the patient is randomized to reinsertion of a Thoracostomy Tube for retained haemothorax
Study: NCT00760721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Small Group Session
Description: 1 hour small group health-related discussion

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Educational Small Group Session
Description: 1 hour small group health-related discussion
Study: NCT03992404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NT 201
Description: Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).